WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H555286
CAS#: 1616413-96-7
Description: UCB9608 is a Potent, Orally Bioavailable PI4KIIIβ Inhibitor. UCB9608 showed the improved metabolic stability and excellent pharmacokinetic profile. UCB9608 is an 11 nM PI4KIIIβ inhibitor that inhibits the HuMLR response with IC50 = 37 nM. Its potency and excellent ADME properties make it an ideal compound for future use as an in vitro and in vivo probe to elucidate the emerging role of PI4KIIIβ inhibition in immune processes.
Hodoodo Cat#: H555286
Name: UCB9608
CAS#: 1616413-96-7
Chemical Formula: C20H26N8O2
Exact Mass: 410.22
Molecular Weight: 410.482
Elemental Analysis: C, 58.52; H, 6.38; N, 27.30; O, 7.80
Synonym: UCB9608; UCB-9608; UCB 9608.
IUPAC/Chemical Name: (3S)-4-(6-amino-1-methyl-pyrazolo[3,4-d]pyrimidin-4-yl)-N-(4-methoxy-2-methyl-phenyl)-3-methyl-piperazine-1-carboxamide
InChi Key: WRONAJQPZWDYAR-ZDUSSCGKSA-N
InChi Code: InChI=1S/C20H26N8O2/c1-12-9-14(30-4)5-6-16(12)23-20(29)27-7-8-28(13(2)11-27)18-15-10-22-26(3)17(15)24-19(21)25-18/h5-6,9-10,13H,7-8,11H2,1-4H3,(H,23,29)(H2,21,24,25)/t13-/m0/s1
SMILES Code: O=C(N1C[C@H](C)N(C2=C3C(N(C)N=C3)=NC(N)=N2)CC1)NC4=CC=C(OC)C=C4C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 410.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Reuberson J, Horsley H, Franklin RJ, Ford D, Neuss J, Brookings D, Huang Q,
Vanderhoydonck B, Gao LJ, Jang M, Herdewijn P, Ghawalkar A, Fallah-Arani F, Khan
A, Henshall J, Jairaj M, Malcolm S, Ward E, Shuttleworth L, Lin Y, Li S, Louat T,
Waer M, Herman J, Payne A, Ceska T, Doyle C, Pitt WR, Calmiano M, Augustin M,
Steinbacher S, Lammens A, Allen R. Discovery of a potent, orally bioavailable
PI4KIIIβ inhibitor (UCB9608) able to significantly prolong allogeneic organ
engraftment in vivo. J Med Chem. 2018 Jun 28. doi: 10.1021/acs.jmedchem.8b00521.
[Epub ahead of print] PubMed PMID: 29952567.